163 related articles for article (PubMed ID: 7476895)
1. Reversible modulation of opioid receptor binding in intact neural cells by endogenous guanosine triphosphate.
Yabaluri N; Medzihradsky F
Mol Pharmacol; 1995 Oct; 48(4):690-5. PubMed ID: 7476895
[TBL] [Abstract][Full Text] [Related]
2. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
3. Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells.
Carter BD; Medzihradsky F
Mol Pharmacol; 1993 Mar; 43(3):465-73. PubMed ID: 8383804
[TBL] [Abstract][Full Text] [Related]
4. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
6. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Clark MJ; Traynor JR
J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
[TBL] [Abstract][Full Text] [Related]
7. Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins.
Selley DE; Breivogel CS; Childers SR
Mol Pharmacol; 1993 Oct; 44(4):731-41. PubMed ID: 8232223
[TBL] [Abstract][Full Text] [Related]
8. Naltrexone-induced upregulation of mu opioid receptors on 7315c cell and brain membranes: enhancement of opioid efficacy in inhibiting adenylyl cyclase.
Côté TE; Izenwasser S; Weems HB
J Pharmacol Exp Ther; 1993 Oct; 267(1):238-44. PubMed ID: 8229750
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
Puttfarcken PS; Werling LL; Cox BM
Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
[TBL] [Abstract][Full Text] [Related]
10. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
[TBL] [Abstract][Full Text] [Related]
11. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
Pak Y; Kouvelas A; Scheideler MA; Rasmussen J; O'Dowd BF; George SR
Mol Pharmacol; 1996 Nov; 50(5):1214-22. PubMed ID: 8913353
[TBL] [Abstract][Full Text] [Related]
12. Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells.
Prather PL; Tsai AW; Law PY
J Pharmacol Exp Ther; 1994 Jul; 270(1):177-84. PubMed ID: 8035314
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
14. Go mediates the coupling of the mu opioid receptor to adenylyl cyclase in cloned neural cells and brain.
Carter BD; Medzihradsky F
Proc Natl Acad Sci U S A; 1993 May; 90(9):4062-6. PubMed ID: 8097884
[TBL] [Abstract][Full Text] [Related]
15. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain.
Chaipatikul V; Loh HH; Law PY
J Pharmacol Exp Ther; 2003 Jun; 305(3):909-18. PubMed ID: 12626655
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling.
Yabaluri N; Medzihradsky F
Mol Pharmacol; 1997 Nov; 52(5):896-902. PubMed ID: 9351981
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
18. 3H-naloxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells: evidence for G-protein-dependent antagonist binding.
Brown GP; Pasternak GW
J Pharmacol Exp Ther; 1998 Jul; 286(1):376-81. PubMed ID: 9655882
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells.
Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL
J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156
[TBL] [Abstract][Full Text] [Related]
20. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
